全球心臟手术设备市场 - 2023-2030

概述

全球心臟手术器械市场将于 2022 年达到 21 亿美元，预计到 2030 年将达到 32 亿美元，2023-2030 年预测期间复合年增长率为 3.4%。

心臟手术设备用于治疗许多心血管疾病，包括先天性心脏病、心律失常和心臟瓣膜疾病。心臟手术设备有助于治疗心臟循环系统的结构问题，包括受损或堵塞的瓣膜和动脉。

近年来，由于起搏器、植入式心律转復除颤器(ICD)、心臟瓣膜、球囊导管和支架等心臟和血管手术设备的使用，全球心臟手术设备市场出现了显着增长，因为它们在管理心臟疾病方面发挥着关键作用。以及治疗心血管疾病。

此外，技术进步的不断进步、产品的推出和优惠的报销政策等重要的增长动力将推动未来的市场增长。 Medtronic plc、Terumo Corporation、LivaNova Plc.、Abbott Laboratories、Murray Surgical Limited、Boston Scientific Corporation 等重要参与者都在市场上积极运营。

动力学

心臟手术设备的技术进步

心臟手术器械用于治疗多种心血管疾病，如缺血性心脏病、风湿性心脏病、充血性心力衰竭、瓣膜性心脏病等。大公司的重大技术进步有助于推动市场增长。这些有效的进步有助于将研究发现转化为新的治疗方法，并改善对数百万心脏病患者的护理。

例如，2023 年 5 月，Robocath 在 EuroPCR 2023 会议上推出了一款名为 R-One+ 的心臟手术机器人系统，用于冠状动脉血管成形术。该平台允许心脏病专家通过位于导管实验室的控制命令单元控制设备。

此外，雅培实验室于 2022 年 12 月推出了最新一代经导管主动脉瓣植入 (TAVI) 系统 Navitor，为手术风险较高或极高的严重主动脉瓣狭窄患者提供微创设备。因此，由于上述因素，预计市场在预测期内将会提振。

有利的报销政策正在提振心臟手术器械市场

报销政策通常会考虑手术的复杂性、使用的导管类型以及手术期间使用的相关医疗资源等因素。报销政策在心臟手术设备市场中发挥着至关重要的作用，因为它们决定了为执行心导管插入术的医疗保健提供者提供的承保范围和财务报销水平。

例如，据 Shockwave Medical 2022 年 7 月报导，自 2021 年初推出冠状动脉 IVL 以来，Shockwave 在报销方面取得了深入而重大的进展。他们在门诊、ASC 和住院机构都有报销。此外，还有机会通过冠状动脉 III 类 CPT 代码获得医生报销。

心导管插入术的并发症将阻碍市场的增长

心导管插入术涉及将导管插入血管，这可能会导致血管损伤。这可能包括血管穿孔、剥离（血管壁撕裂）或破裂。血管损伤可能导致出血、血肿形成，甚至需要手术修復。

根据心血管组织 2023 年 4 月的报告，与心导管插入术相关的最常见风险是出血。在手术过程中，会做一个小切口来插入导管，这可能会导致出血。心导管插入术期间或之后可能会发生称为心律失常的心律异常。这些可能是由于手术过程中血流的变化或导管与心肌的摩擦造成的。

目录

第 1 章：方法和范围

• 研究方法论
• 报告的研究目的和范围

第 2 章：定义和概述

第 3 章：执行摘要

• 按产品分类的片段
• 程序片段
• 应用程序片段
• 最终用户摘录
• 按地区分類的片段

第 4 章：动力学

• 影响因素
  • 司机
    • 心臟手术设备的技术进步
    • 优惠报销政策
  • 限制
    • 心导管插入术的并发症
  • 机会
  • 影响分析

第 5 章：行业分析

• 波特五力分析
• 供应链分析
• 未满足的需求
• 监管分析
• DMI 意见

第 6 章：COVID-19 分析

• COVID-19 分析
  • COVID-19 之前的情况
  • COVID-19 期间的情况
  • COVID-19 后的情景
• COVID-19 期间的定价动态
• 供需谱
• 疫情期间政府与市场相关的倡议
• 製造商的战略倡议
• 结论

第 7 章：副产品

• 心臟跳动手术系统
  • 稳定剂
  • 定位器
• 心肺旁路设备
  • 动脉插管
  • 静脉插管
  • 制氧机
• 导管
  • 球囊导管
  • 消融导管
  • 引流管
• 灌註一次性用品
  • 动脉过滤器
  • 连接器
  • 血液浓缩器

第 8 章：按程序

• 冠状动脉搭桥术
• 微创手术
• 其他的

第 9 章：按应用

• 先天性心脏病
• 冠状动脉疾病
• 心律失常
• 心臟瓣膜疾病
• 其他的

第 10 章：最终用户

• 医院
• 心臟中心
• 门诊手术中心
• 其他的

第 11 章：按地区

• 北美
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 欧洲其他地区
• 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太地区其他地区
• 中东和非洲

第 12 章：竞争格局

• 竞争场景
• 产品基准化分析
• 公司股份分析
• 主要进展和策略

第 13 章：公司简介

• Medtronic Plc
• 公司简介
• 产品组合和描述
• 财务概览
• 主要进展
• Terumo Corporation
• LivaNova Plc
• Abbott Laboratories
• Murray Surgical Limited
• Boston Scientific Corporation
• Getinge AB
• Wexler Surgical
• Lepu Medical Technology Co. Ltd.
• Gore Medical Inc.

第 14 章：附录

Overview

Global Cardiac Surgery Devices Market reached US$ 2.1 billion in 2022 and is expected to reach US$ 3.2 billion by 2030 growing with a CAGR of 3.4% during the forecast period 2023-2030.

Cardiac surgery devices are used in the treatment of many cardiovascular diseases including congenital heart disease, arrhythmias, and heart valve disease. Cardiac surgery devices aid in the healing of structural problems in the circulatory system of the heart including damaged or clogged valves and arteries.

The global cardiac surgery devices market has witnessed significant growth in recent years due to the usage of cardiac and vascular surgery devices such as pacemakers, implantable cardioverter defibrillators (ICDs), heart valves, balloon catheters, and stents as they play a key role in managing and treating cardiovascular diseases.

Furthermore, significant growth drivers such as increasing technological advancements, product launches, and favorable reimbursement policies give rise to future market growth. Significant key players like Medtronic plc, Terumo Corporation, LivaNova Plc., Abbott Laboratories, Murray Surgical Limited, Boston Scientific Corporation, and others are actively operating in the market.

Dynamics

Technological Advancements in Cardiac Surgery Devices

Cardiac surgery devices are used to treat many cardiovascular diseases such as ischemic heart disease, rheumatic heart disease, congestive heart failure, and valvular heart disease. The major technological advancements by major companies help to drive market growth. These effective advancements help to transform research discoveries into new treatments and improve care for millions of people with heart diseases.

For instance, in May 2023, Robocath launched a robot system for heart surgery called R-One+, for coronary angioplasties at the EuroPCR 2023 conference. The platform allows the cardiologist to control devices from the control command unit which can be positioned in the catheterization laboratory.

Additionally, in December 2022, Abbott Laboratories launched its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, by making the minimally invasive device available for people with severe aortic stenosis who are at high or extreme surgical risk. Hence, due to the above factors, the market is expected to boost over the forecast period.

Favorable Reimbursement Policies are Boosting the Cardiac Surgery Device Market

Reimbursement policies often consider factors such as the complexity of the procedure, the type of catheter used, and the associated healthcare resources utilized during the procedure. Reimbursement policies play a crucial role in the cardiac surgery device market as they determine the level of coverage and financial reimbursement provided to healthcare providers for performing cardiac catheterization procedures.

For instance, according to Shockwave Medical July 2022, since the launch of Coronary IVL in early 2021, Shockwave has made deep and significant progress on reimbursement. They have reimbursement in the outpatient, ASC, and inpatient settings. In addition, an opportunity for physician reimbursement via Coronary Category III CPT code.

Complications for Cardiac Catheterization Will Hamper the Growth of the Market

Cardiac catheterization involves the insertion of a catheter into blood vessels, which can potentially cause vessel damage. This can include vessel perforation, dissection (tearing of the vessel wall), or rupture. Vessel damage can result in bleeding, hematoma formation, or even require surgical repair.

According to CardioVascular Group, April 2023, the most common risk associated with cardiac catheterization is bleeding. During the procedure, a small incision is made to insert the catheter, and this can lead to bleeding. Heart rhythm abnormalities called arrhythmias can happen during or after cardiac catheterization. These can result from changes in blood flow during the procedure or from the catheter rubbing against the heart muscle.

Segment Analysis

The global cardiac surgery devices market is segmented based on product, procedure, application, end users, and region.

Catheters from the Product Segment Accounted for Approximately 47.2% of the Global Cardiac Surgery Devices Market Share

The catheterization procedure is typically carried out in patients by using various catheters with certain congenital heart defects, such as transposition of the great arteries or pulmonary atresia, where there is an abnormal communication or inadequate blood flow between the atria. The demand for catheters is driven by the increasing incidence of cardiovascular diseases.

For instance, in May 2023, Abbott Laboratories received the approval of the U.S. Food and Drug Administration (FDA) for the company's TactiFlex Ablation Catheter which is sensor-enabled and the world's first ablation catheter with a flexible tip and contact force technology.

Additionally, in May 2022, Medtronic Plc. received approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, a drug-coated balloon (DCB), indicated for the interventional treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries.

Geographical Penetration

North America Accounted for Approximately 38.5% of the Market Share in 2022

North America has maintained a significant proportion of the cardiac surgery devices market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising number of open heart surgeries performed in the U.S. and technological advancements in cardiac surgery devices.

For instance, according to the Lifespan Health System, there are about 500,000 open heart surgeries performed each year in the United States. It is most often used for complicated procedures, such as coronary artery bypass, or complex procedures to the aorta or the heart itself. Also, coronary heart disease is the most common type of heart disease, killing 375,476 people in 2021.

Competitive Landscape

The major global players in the market include: Medtronic Plc., Terumo Corporation, LivaNova Plc., Abbott Laboratories, Murray Surgical Limited, Boston Scientific Corporation, Getinge AB, Wexler Surgical, Lepu Medical Technology Co. Ltd, and Gore Medical Inc. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the cardiac surgery device market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, device implantations, and consultations worldwide. Many hospitals are focused on COVID-19 cases, and this reduced cardiac surgery in many patients suffering from congenital heart defects.

Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the cardiac surgery device market is expected to be moderately affected over the forecast period.

By Product

• Beating Heart Surgery Systems
  • Stabilizers
  • Positioners

• Cardiopulmonary Bypass Equipment
  • Arterial cannula
  • Venous cannula
  • Oxygenators

• Catheters
  • Balloon catheter
  • Ablation Catheter
  • Drainage Catheter

• Perfusion Disposables
  • Arterial Filters
  • Connectors
  • Hemoconcentrator

• Others

By Procedure

• Coronary Artery Bypass Grafting
• Minimally Invasive Surgery
• Others

By Application

• Congenital Heart Disease
• Coronary Artery Disease
• Arrhythmias
• Heart Valve Disease
• Rheumatic Heart Disease
• Aortic Aneurysm
• Congestive Heart Failure
• Others

By End Users

• Hospital
• Cardiac Centers
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In March 2023, Shockwave Medical launched the new peripheral IVL catheter. The Shockwave L6 catheter is purpose-built to modify calcification in otherwise difficult-to-treat lesions in large peripheral vessels, including the iliac and the common femoral arteries.
• In June 2023, Terumo Aortic launched of the company's global post-approval study (PAS) known as EXTEND for Thoraflex Hybrid, the only frozen elephant trunk (FET) device approved by the US Food and Drug Administration (FDA) for the treatment of patients with complex aortic arch disease.

Why Purchase the Report?

• To visualize the global cardiac surgery devices market segmentation based on product, procedure, application, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global cardiac surgery devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global cardiac surgery devices market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Procedure
• 3.3. Snippet by Applications
• 3.4. Snippet by End Users
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Technological advancements in cardiac surgery devices
    • 4.1.1.2. Favorable reimbursement policies
  • 4.1.2. Restraints
    • 4.1.2.1. Complications for cardiac catheterization
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis
• 5.5. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. By Product

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.1.2. Market Attractiveness Index, By Product
• 7.2. Beating Heart Surgery System
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Stabilizers
  • 7.2.4. Positioners
• 7.3. Cardiopulmonary Bypass Equipment
  • 7.3.1. Arterial cannula
  • 7.3.2. Venous cannula
  • 7.3.3. Oxygenators
• 7.4. Catheters
  • 7.4.1. Balloon catheter
  • 7.4.2. Ablation Catheter
  • 7.4.3. Drainage Catheter
• 7.5. Perfusion Disposables
  • 7.5.1. Arterial Filters
  • 7.5.2. Connectors
  • 7.5.3. Hemoconcentrator

8. By Procedure

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
  • 8.1.2. Market Attractiveness Index, By Procedure
• 8.2. Coronary Artery Bypass Grafting
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Minimally Invasive Surgery
• 8.4. Others

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Congenital Heart Disease
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Coronary Artery Disease
• 9.4. Arrhythmias
• 9.5. Heart Valve Disease
• 9.6. Others

10. By End Users

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.1.2. Market Attractiveness Index, By End Users
• 10.2. Hospitals
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Cardiac Centers
• 10.4. Ambulatory Surgical Centers
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
  • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Product Benchmarking
• 12.3. Company Share Analysis
• 12.4. Key Developments and Strategies

13. Company Profiles

• 13.1. Medtronic Plc*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Terumo Corporation
• 13.3. LivaNova Plc
• 13.4. Abbott Laboratories
• 13.5. Murray Surgical Limited
• 13.6. Boston Scientific Corporation
• 13.7. Getinge AB
• 13.8. Wexler Surgical
• 13.9. Lepu Medical Technology Co. Ltd.
• 13.10. Gore Medical Inc.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us